Candel Therapeutics, Inc. (CADL) - Q2 2025 10-Q Summary
Business Context and Reporting Period
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies for cancer. The company focuses on two primary product candidates: CAN-2409 (aglatimagene besadenovec), an adenovirus-based therapy, and CAN-3110 (linoserpaturev), a herpes simplex virus (HSV)-based therapy. This report covers the quarterly period ended June 30, 2025.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income (Loss) | $(4,796) | $(22,237) | $2,583 | $(30,458) |
| Operating Expenses | $11,177 | $8,571 | $19,307 | $16,473 |
| Cash and Cash Equivalents | $100,687 | $102,654 | $100,687 | $35,679 |
| Total Debt (Current + Long-term) | $7,643 | $11,628 | $7,643 | $11,628 |
| Warrant Liability | $1,146 | $21,718 | $1,146 | $21,718 |
Note: The company reported a net income of $2.6 million for the six months ended June 30, 2025, primarily driven by a $20.6 million gain from the change in fair value of warrant liabilities, offset by operating losses.
Material Changes vs. Prior Period
- Net Income Turnaround: The company shifted from a net loss of $30.5 million in the first half of 2024 to a net income of $2.6 million in the first half of 2025. This is largely attributable to a non-cash gain of $20.6 million from the revaluation of warrant liabilities, compared to a loss of $13.3 million in the prior year period.
- Operating Expenses: Total operating expenses increased by 17% year-over-year for the six-month period ($19.3M vs. $16.5M). Research and Development (R&D) expenses rose by $1.9 million, driven by increased clinical development and manufacturing costs for CAN-2409.
- Liquidity Position: Cash and cash equivalents increased significantly to $100.7 million as of June 30, 2025, compared to $35.7 million at the end of the prior year period. This increase was fueled by a $92.0 million public offering in December 2024 and a $15.0 million registered direct offering in June 2025.
- Debt Reduction: The company reduced its term loan payable to Silicon Valley Bank (SVB) by $5.0 million during the six months ended June 30, 2025, bringing the total outstanding debt to approximately $7.6 million.
Guidance, Outlook, and Management Commentary
- Clinical Milestones:
- CAN-2409 (Prostate Cancer): In December 2024, the company announced positive topline data from its Phase 3 trial in intermediate-to-high-risk localized prostate cancer, meeting the primary endpoint of Disease-Free Survival (DFS). The company anticipates submitting a Biologics License Application (BLA) in the fourth quarter of 2026.
- CAN-2409 (NSCLC & Pancreatic Cancer): Positive survival data was announced in early 2025 for Non-Small Cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC). The company plans to advance enabling work for potentially registrational trials in these indications.
- CAN-3110 (Glioma): The company is conducting an investigator-sponsored Phase 1b trial in recurrent high-grade glioma. Final overall survival readouts are expected in the fourth quarter of 2025.
- Liquidity Outlook: Management believes existing cash resources of $100.7 million are sufficient to fund operations into the first quarter of 2027.
- Risks and Contingencies:
- Regulatory Uncertainty: While the FDA granted a Special Protocol Assessment (SPA) for the Phase 3 prostate cancer trial, approval is not guaranteed. The company faces risks related to the novel nature of viral immunotherapies.
- Compliance Issues: The filing discloses that in March 2024, the company identified that a former CEO allegedly instructed personnel to falsify sterility testing results for CAN-2409. The company stated it has remediated the issue, updated its stability testing program, and determined there is no risk to the integrity of clinical data or patient safety.
- Capital Needs: The company will require substantial additional funding to complete clinical development and commercialization. Failure to raise capital could force delays or elimination of programs.
Investor Verification Checklist
- BLA Timeline: Verify the feasibility of the Q4 2026 BLA submission for CAN-2409 in prostate cancer given the manufacturing and regulatory requirements.
- Compliance Remediation: Confirm the status of FDA communications regarding the March 2024 sterility testing irregularities and ensure no clinical holds are in place.
- Warrant Liability Volatility: Monitor the fair value of the remaining warrant liability ($1.1M), as fluctuations will continue to impact reported net income/loss without affecting cash flow.
- Cash Burn Rate: Assess the sustainability of the $100.7M cash balance against the projected burn rate for advancing Phase 3 trials in NSCLC and PDAC.
- Debt Covenants: Review the terms of the SVB term loan (maturing Jan 1, 2026) to ensure compliance with covenants and repayment schedules.